比利时多中心产前游离DNA筛查技术纵向性能监测
本研究在比利时全国产前游离DNA筛查人群中,3年内记录1158例阳性后诊断性检测,分析不同技术的阳性预测值。结果显示21三体阳性预测值范围92.2%至65.7%,18三体82.8%至44.4%,13三体40%至18.2%,实验室自建检测总体优于商业检测。
要点
- 阳性预测值因技术而异,21三体最高92.2%,13三体最低18.2%
- 实验室自建检测总体表现优于商业检测
- 尽管特异性高,阳性预测值差异对孕妇和卫生系统影响显著
核心结论
- 商业检测和实验室自建检测的准确性得到证实,但实验室自建检测总体优于商业检测。
- 尽管各检测特异性高,阳性预测值差异显著影响孕妇和国家医疗系统。
研究设计与样本
- 比利时全国性产前游离DNA筛查,无论孕妇 priori 风险均提供。
- 3年内记录所有阳性后诊断性检测共1158例,并记录所用技术及结局。
- 按技术计算三种常见胎儿三体的阳性预测值。
主要发现
- 1158例诊断性检测中,58.5%来自实验室自建检测,15.7%来自VeriSeq,6.6%来自Harmony,5%来自Vanadis,14.2%技术无法追溯。
- 21三体阳性预测值范围92.2%至65.7%。
- 18三体阳性预测值范围82.8%至44.4%。
- 13三体阳性预测值范围40%至18.2%。
临床怎么用
- 临床解读阳性筛查结果时应考虑所用技术,因阳性预测值差异显著。
- 实验室自建检测在真实世界中表现优于商业检测,可优先考虑。
局限性
- 14.2%的阳性后诊断性检测技术无法追溯。
- 未报告各技术具体样本量及置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prenatal cell-free DNA screening is widely used to assess the risk of fetal trisomy 21, 18, and 13. Although commercial and laboratory-developed tests (LDTs) show high accuracy in validation studies, real-world longitudinal performance data are lacking. METHOD: In Belgium, prenatal cell-free DNA screening is a population screening offered to all pregnant people, regardless of their a priori risk. Over 3 years, all confirmatory diagnostic tests after a positive prenatal cell-free DNA screening result were recorded along with the technologies used and their outcomes. Positive predictive values (PPVs) for the three common fetal trisomies were calculated per technology. RESULTS: A total of 1158 diagnostic tests were performed after a positive prenatal cell-free DNA screening. Of these, 58.5% came from an LDT, 15.7% from VeriSeq (Illumina), 6.6% from Harmony (Roche), 5% from Vanadis (Perkin-Elmer); for 14.2% the technology could not be traced. PPVs ranged from 92.2% to 65.7% for trisomy 21, from 82.8% to 44.4% for trisomy 18, and from 40% to 18.2% for trisomy 13. Overall, the LDT performed better than the commercial tests. CONCLUSION: This study confirms the reported accuracy of commercial tests and LDT, while showing that LDT generally outperforms commercial tests. Despite high specificities across tests, differences in PPVs significantly impact pregnant people and the national health care system.
引用
- Duquenne A, Brison N, Parijs I, et al. Multicentric Longitudinal Performance Monitoring of Different Prenatal Cell-Free DNA Screening Technologies in Belgium. Prenat Diagn. 2026. PMID: 42607131. doi:10.1002/pd.70236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。